Fig. 6

miR-206 enhances EOC chemoresistance to cisplatin in vivo. Xenograft tumor growth derived from subcutaneously injected EOC cells stably transfected with p-EGP-miR-206 plasmids (A2780s-206 and OV2008-206) or vector control plasmids (A2780s-con and OV2008-con) in 20 female SCID mice. Tumors were allowed to grow to approximately 100 mm3 for A2780s and 50 mm3 for OV2008, and then the mice were given 4 mg/kg cisplatin through intraperitoneal injection once every 3 days. a Tumors developed in the four groups of mice before the dissection of tumors. b Tumor volume in SCID mice was measured every two days before cisplatin treatment (some tumors are indicated by arrows). c Tumor volume in SCID mice was measured every two days after cisplatin treatment. d Tumor weight of SCID mice at the termination of the experiments. e qRT-PCR showed miR-206 expression in implanted tumors derived from EOCs stably transfected with miR-206 and empty vector